Medifron DBT Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.00%

Medifron DBT Co. Ltd (065650) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 065650 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

₩470.00

≈ $0.32 USD Cash + Short-term Investments

Total Assets

₩113.62 Billion

≈ $77.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Medifron DBT Co. Ltd's Asset Resilience Ratio has changed over time. See Medifron DBT Co. Ltd net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Medifron DBT Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Medifron DBT Co. Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩470.00	0.0%
Total Liquid Assets	₩470.00	0.00%

Asset Resilience Insights

Limited Liquidity: Medifron DBT Co. Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Medifron DBT Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Medifron DBT Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Medifron DBT Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Medifron DBT Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	12.61%	₩7.62 Billion ≈ $5.16 Million	₩60.40 Billion ≈ $40.94 Million	-10.69pp
2023-12-31	23.30%	₩13.00 Billion ≈ $8.81 Million	₩55.79 Billion ≈ $37.81 Million	-23.65pp
2022-12-31	46.95%	₩26.18 Billion ≈ $17.74 Million	₩55.75 Billion ≈ $37.78 Million	+27.36pp
2021-12-31	19.59%	₩9.62 Billion ≈ $6.52 Million	₩49.10 Billion ≈ $33.27 Million	-9.97pp
2020-12-31	29.57%	₩13.96 Billion ≈ $9.46 Million	₩47.22 Billion ≈ $32.00 Million	-21.61pp
2019-12-31	51.17%	₩9.96 Billion ≈ $6.75 Million	₩19.46 Billion ≈ $13.19 Million	-14.19pp
2018-12-31	65.37%	₩14.10 Billion ≈ $9.56 Million	₩21.57 Billion ≈ $14.62 Million	+8.58pp
2017-12-31	56.78%	₩14.90 Billion ≈ $10.10 Million	₩26.24 Billion ≈ $17.78 Million	+37.45pp
2016-12-31	19.33%	₩5.37 Billion ≈ $3.64 Million	₩27.75 Billion ≈ $18.81 Million	+9.60pp
2015-12-31	9.73%	₩3.00 Billion ≈ $2.03 Million	₩30.84 Billion ≈ $20.90 Million	+1.04pp
2014-12-31	8.69%	₩2.30 Billion ≈ $1.56 Million	₩26.48 Billion ≈ $17.95 Million	--

pp = percentage points

About Medifron DBT Co. Ltd

KQ:065650 Korea Biotechnology

Market Cap

$19.03 Million

₩28.08 Billion KRW

Market Cap Rank

#25173 Global

#1873 in Korea

Share Price

₩2110.00

Change (1 day)

+10.18%

52-Week Range

₩210.00 - ₩6090.00

All Time High

₩8800.00